The US Food and Drug Administration has granted its first approval to AstraZeneca and Daiichi Sankyo’s novel antibody-drug conjugate, datopotamab deruxtecan (Dato-DXd), for use in breast cancer. Launch is expected within two weeks.
US Dato-DXd Approval Relief For AstraZeneca and Daiichi Sankyo
The FDA green light for Datroway in breast cancer marks the first for a TROP2-directed antibody-drug conjugate and is a relief for partners AstraZeneca and Daiichi Sankyo after multiple filing mis-steps in its lung cancer indication.
